Home › Ovarian Cancer › NCT06295965

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers (CHANCES)

Who can join

All ages · All sexes

Inclusion Criteria:

* Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and:

  * Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy

OR

* Subjects who have or have had a solid tumor diagnosis and any of the following:

  * At least 4 months of exposure to a PARP inhibitor
  * Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm

Exclusion Criteria:

* Individuals with a life expectancy of less than 6 months

About the study

This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.

What is being tested

• Non-Interventional Study (other)

Sponsor: University of Washington · Participants: 2,000 · Started: Jan 2, 2024

Contact the study team

• Swisher Lab Research Coordinators · Phone: 206-616-8927

Official record on ClinicalTrials.gov — NCT06295965

Locations in the U.S.

Conditions

• Ovarian Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.